Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Author(s):
Heijde, D. van der; Wei, J.C.C.; Dougados, M.; Mease, P.; Deodhar, A.; Maksymowych, W.P.; Bosch, F. van den; Sieper, J.; Tomita, T.; Landewe, R.; Zhao, F.Y.; Krishnan, E.; Adams, D.H.; Pangallo, B.; Carlier, H.; COAST-V Study Grp
